Company Overview and News

 
CKI Western Utilities: A Chinese Valuation

2017-11-02 seekingalpha
CKI trades at a discount to competitors with poor balance sheets and has a relatively low payout ratio which results in superior growth of both earnings and dividends going forward.

 
FIRB okays CKI's $7.5bn Duet bid

2017-04-21 businessnews.com.au
Australia's Foreign Investment Review Board has approved a $7.48 billion takeover offer for energy utliity operator DUET Group by a Hong Kong consortium led by Cheung Kong Infrastructure.

 
DUET-Cheung Kong deal to test Australia's foreign investment regime

2017-01-16 in.reuters
SYDNEY/HONG KONG DUET Group has agreed to recommend an increased $5.51 billion bid from a consortium led by Cheung Kong Infrastructure Holdings, in a deal that is likely to test Australia's appetite for foreign investment in its key energy assets.

 
DUET-Cheung Kong deal to test Australia's foreign investment regime

2017-01-16 theedgemarkets
SYDNEY (Jan 16): DUET Group has agreed to recommend an increased US$5.51 billion bid from a consortium led by Cheung Kong Infrastructure Holdings, in a deal that is likely to test Australia's appetite for foreign investment in its key energy assets.

 
Li Ka-shing's Cheung Kong Infrastructure makes $7.3 billion offer for Duet Group

2016-12-04 theage.com.au
A company led by Asia's second-richest man Li Ka-shing has made a $7.3 billion bid for infrastructure owner Duet Group, just four months after the Turnbull government blocked the purchase of NSW's poles and wires business by the same group.

 
Li Ka-shing's Cheung Kong Infrastructure makes $7.3 billion offer for Duet Group

2016-12-04 smh.com.au
A company led by Asia's second-richest man Li Ka-shing has made a $7.3 billion bid for infrastructure owner Duet Group, just four months after the Turnbull government blocked the purchase of NSW's poles and wires business by the same group.

 
Li Ka-Shing's Australian Gas Networks sues Australian financial adviser Goldman Sachs

2016-09-15 theage.com.au
Asia's second richest person Li Ka-Shing is suing his Australian financial advisors from Goldman Sachs Australia over $15.9 million in incorrectly charged fees linked to his takeover of one of Australia's biggest gas companies.

 
Li Ka-Shing's Australian Gas Networks sues Australian financial adviser Goldman Sachs

2016-09-15 smh.com.au
Asia's second richest person Li Ka-Shing is suing his Australian financial advisors from Goldman Sachs Australia over $15.9 million in incorrectly charged fees linked to his takeover of one of Australia's biggest gas companies.

 
PRESS DIGEST- Financial Times - April 26

2016-04-26 reuters
April 26 The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.

 
Husky selling part interest in midstream assets for C$1.7 billion

2016-04-25 reuters
CALGARY, Alberta Husky Energy (HSE.TO) said on Monday it will sell 65 percent ownership in select midstream energy assets in Canada to Cheung Kong Infrastructure Holdings Ltd (1038.HK) and Power Asset Holdings Ltd (0006.HK) for C$1.7 billion ($1.34 billion).

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...